CG Oncology (NASDAQ:CGON) Shares Up 18.3%

CG Oncology, Inc. (NASDAQ:CGON) shares traded up 18.3% during trading on Friday . The stock traded as high as $46.99 and last traded at $46.74. 100,653 shares changed hands during trading, a decline of 83% from the average session volume of 607,582 shares. The stock had previously closed at $39.50.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Morgan Stanley started coverage on CG Oncology in a research note on Tuesday, February 20th. They issued an “overweight” rating and a $55.00 price target for the company. The Goldman Sachs Group started coverage on shares of CG Oncology in a research note on Tuesday, February 20th. They set a “neutral” rating and a $42.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of CG Oncology in a report on Thursday, April 4th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $75.00 target price on shares of CG Oncology in a report on Thursday.

CG Oncology Trading Down 8.2 %

The company’s 50-day moving average price is $39.78.

Institutional Investors Weigh In On CG Oncology

A hedge fund recently bought a new stake in CG Oncology stock. BNP Paribas Financial Markets bought a new stake in shares of CG Oncology, Inc. (NASDAQ:CGON) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 11,198 shares of the company’s stock, valued at approximately $492,000. Institutional investors own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.